1 <u>TITLE</u>

- 2 Diagnostic Utility of Genome-wide DNA Methylation Analysis in Genetically Unsolved
- 3 Developmental and Epileptic Encephalopathies and Refinement of a CHD2 Episignature
- 4

5 AUTHORS AND AFFILIATIONS

6 Christy W. LaFlamme^{1,2*}, Cassandra Rastin^{3,4*}, Soham Sengupta¹, Helen E. Pennington^{1,5}, Sophie J. Russ-Hall⁶, Amy L. Schneider⁶, Emily S. Bonkowski¹, Edith P. Almanza Fuerte¹, 7 Miranda Galey⁷, Joy Goffena⁷, Sophia B. Gibson^{7,8}, Talia J. Allan⁶, Denis M. Nyaga⁹, Nico 8 Lieffering⁹, Malavika Hebbar⁷, Emily V. Walker¹⁰, Daniel Darnell¹⁰, Scott R. Olsen¹⁰, Pandurang 9 Kolekar¹¹, Nahdir Djekidel¹², Wojciech Rosikiewicz¹², Haley McConkey⁴, Jennifer Kerkhof⁴, 10 Michael A. Levy⁴, Raissa Relator⁴, Dorit Lev¹³, Tally Lerman-Sagie^{14,15}, Kristen L. Park¹⁶, Marielle 11 Alders¹⁷, Gerarda Cappuccio^{18,19}, Nicolas Chatron^{20,21}, Leigh Demain²², David Genevieve²³, 12 Gaetan Lesca^{20,21}, Tony Roscioli²⁴⁻²⁷, Damien Sanlaville^{20,21}, Matthew L. Tedder²⁸, Monika Weisz 13 14 Hubshman^{29,30}, Shamika Ketkar²⁹, Hongzheng Dai²⁹, Kim Carlyle Worley²⁹, Jill A. Rosenfeld²⁹, Hsiao-Tuan Chao^{29,31-35}, Undiagnosed Diseases Network, Geoffrey Neale¹⁰, Gemma L. Carvill³⁶, 15 University of Washington Center for Rare Disease Research, Zhaoming Wang^{11,37}, Samuel F. 16 Berkovic⁶, Lynette G. Sadleir⁹, Danny E. Miller^{7,38-39}, Ingrid E. Scheffer^{6,40-41}, Bekim Sadikovic^{3,4#}, 17 Heather C. Mefford^{1#} 18

19

²⁰ ¹Center for Pediatric Neurological Disease Research, St. Jude Children's Research Hospital,

- 21 Memphis, TN 38105, USA
- ²Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN
 38105, USA

- ³Department of Pathology & Laboratory Medicine, Western University, London, Ontario, N5A
- 25 3K7, Canada
- ⁴Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, N6A
- 27 5W9, Canada
- ⁵Department of Mathematics & Statistics, Rhodes College, Memphis, TN 38112, USA
- ⁶Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health,
- 30 Heidelberg, Victoria 3084, Australia
- ³¹⁷Division of Genetic Medicine, Department of Pediatrics, University of Washington and Seattle
- 32 Children's Hospital, Seattle, WA 98195, USA
- ³³ ⁸Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA
- 34 98195, USA
- ⁹Department of Paediatrics and Child Health, University of Otago, Wellington 6242, New
- 36 Zealand
- ¹⁰Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital
- 38 Memphis, TN 38105, USA
- ¹¹Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN,
 38105, USA
- ¹² Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN,
- 42 38105, USA
- ⁴³ ¹³Institute of Medical Genetics, Wolfson Medical Center, Holon 58100, Israel
- ¹⁴Fetal Neurology Clinic, Pediatric Neurology Unit, Wolfson Medical Center, Holon 58100, Israel
- 45 ¹⁵Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

- ¹⁶Departments of Pediatrics and Neurology, University of Colorado School of Medicine, Aurora,
- 47 CO 80045, USA
- ⁴⁸ ¹⁷Amsterdam UMC, University of Amsterdam, Department of Human Genetics, Amsterdam
- 49 Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ Amsterdam,
- 50 Netherlands
- ¹⁸Telethon Institute of Genetics and Medicine, Pozzuoli, Italy
- ¹⁹Department of Translational Medicine, Federico II University of Naples, Naples, Italy
- ²⁰Department of Medical Genetics, Member of the ERN EpiCARE, University Hospital of Lyon
- 54 and Claude Bernard Lyon I University, Lyon France
- ²¹Pathophysiology and Genetics of Neuron and Muscle (PNMG), UCBL, CNRS UMR5261 -
- 56 INSERM U1315, Lyon, France
- ²²Manchester Centre for Genomic Medicine, United Kingdom
- ²³Montpellier University, Reference Center for Rare Disease, Medical Genetic Department for
- 59 Rare Disease and Personalize Medicine, Inserm Unit 1183, CHU Montpellier, Montpellier,
- 60 France
- ⁶¹²⁴Neuroscience Research Australia (NeuRA), Sydney, Australia
- ²⁵Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney,
- 63 Australia
- ²⁶New South Wales Health Pathology Randwick Genomics, Prince of Wales Hospital, Sydney,
- 65 Australia
- ²⁷Centre for Clinical Genetics, Sydney Children's Hospital, Sydney, Australia
- ²⁸Greenwood Genetic Center, Greenwood, SC, 29646, USA

- ²⁹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX
- 69 77030, USA
- ³⁰Texas Children's Hospital, Genetic Department, Houston, TX 77030, USA
- ³¹Department of Pediatrics, Section of Neurology and Developmental Neuroscience, Baylor
- 72 College of Medicine, Houston, TX 77030, USA
- ³²Cain Pediatric Neurology Research Foundation Laboratories, Jan and Dan Duncan
- Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA, 77030
- ³³Texas Children's Hospital, Houston, TX 77030, USA
- ³⁴Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA
- ³⁵McNair Medical Institute, The Robert and Janice McNair Foundation, Houston, TX 77030,
- 78 USA
- ³⁶Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of
 Medicine, Chicago, IL, USA
- ³⁷Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital,
- 82 Memphis, TN 38105, USA
- ³⁸Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA
 98195, USA
- ³⁹Brotman Baty Institute for Precision Medicine, University of Washington, Seattle, WA 98195,
 USA
- ⁴⁰Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne,
 Australia
- ⁴¹Florey Institute and Murdoch Children's Research Institute, Melbourne, Australia

90

- 91 *These authors contributed equally.
- 92 [#]Correspondence: <u>Heather.Mefford@stjude.org</u> and <u>Bekim.Sadikovic@lhsc.on.ca</u>

93

94 **Keywords**: DNA methylation, unsolved, epilepsy, long-read sequencing, nanopore

95 ABSTRACT

Sequence-based genetic testing currently identifies causative genetic variants in ~50% of 96 individuals with developmental and epileptic encephalopathies (DEEs). Aberrant changes in DNA 97 methylation are implicated in various neurodevelopmental disorders but remain unstudied in 98 99 DEEs. Rare epigenetic variations ("epivariants") can drive disease by modulating gene expression 100 at single loci, whereas genome-wide DNA methylation changes can result in distinct "episignature" biomarkers for monogenic disorders in a growing number of rare diseases. Here, 101 102 we interrogate the diagnostic utility of genome-wide DNA methylation array analysis on peripheral 103 blood samples from 516 individuals with genetically unsolved DEEs who had previously undergone extensive genetic testing. We identified rare differentially methylated regions (DMRs) 104 and explanatory episignatures to discover causative and candidate genetic etiologies in 10 105 106 individuals. We then used long-read sequencing to identify DNA variants underlying rare DMRs. 107 including one balanced translocation, three CG-rich repeat expansions, and two copy number variants. We also identify pathogenic sequence variants associated with episignatures; some had 108 109 been missed by previous exome sequencing. Although most DEE genes lack known 110 episignatures, the increase in diagnostic yield for DNA methylation analysis in DEEs is 111 comparable to the added yield of genome sequencing. Finally, we refine an episignature for CHD2 using an 850K methylation array which was further refined at higher CpG resolution using bisulfite 112 sequencing to investigate potential insights into CHD2 pathophysiology. Our study demonstrates 113 114 the diagnostic yield of genome-wide DNA methylation analysis to identify causal and candidate 115 genetic causes as $\sim 2\%$ (10/516) for unsolved DEE cases.

116 <u>KEYWORDS</u>: DNA methylation; epivariant; episignature; molecular diagnostics; developmental
 117 and epileptic encephalopathies

118

119 **INTRODUCTION**

120 The developmental and epileptic encephalopathies (DEEs) are the most severe group of epilepsies, defined by frequent epileptiform activity associated with developmental slowing or 121 regression¹. While each genetic etiology is rare, with more than 825 genes implicated², the 122 123 cumulative incidence of DEEs overall is 1 in 590 children³. Currently, de novo, X-linked, or 124 recessively inherited pathogenic germline variants are found in ~50% of individuals with DEEs who undergo genetic testing⁴. These are identified by gene panels, exome sequencing (ES), and 125 now, genome sequencing (GS)⁵⁻⁷. A smaller subset is explained by copy number variants 126 127 (CNVs)⁸. Understanding the etiology guides management, such as clinical trial participation, informs accurate reproductive counseling, enables families to join gene-based support groups, 128 and facilitates the development of targeted therapies⁹⁻¹². This, in turn, improves outcomes but is 129 not possible when the etiology is unknown ("unsolved"). 130

Epigenetic modifications, which alter the DNA without changing the DNA nucleotide 131 sequence, determine the etiology of some individuals with neurodevelopmental disorders but 132 133 have not yet been studied in the DEEs. DNA methylation is an essential epigenetic modification that regulates cellular gene expression by adding a methyl (CH_3) group to a DNA strand, typically 134 at CpG sites. This can occur through methylation of promoter CpGs, genomic imprinting, and X-135 chromosome inactivation¹³. Rare epigenetic variations ("epivariants") disrupt normal methylation 136 137 and cause disease. While DNA methylation does not change the DNA sequence itself, epivariants are often perpetrated by underlying in-cis DNA changes, such as rare sequence variants, 138 structural alterations, and CG-rich repeat expansions¹⁴ that are difficult to identify by standard 139 140 sequencing. One example is the methylation of the 5' untranslated region (5'UTR) of FMR1 (MIM:309550) that represses gene expression and causes Fragile X syndrome (MIM:300624). 141 Similarly, hypermethylation of the 5'UTR of Xylosyltransferase 1 (XYLT1, MIM:608124), leading 142 to gene silencing, may identify the "missing" allele in the recessive disease Baratela-Scott 143

syndrome (BSS [MIM:615777])¹⁵. In both Fragile X and BSS, the aberrant methylation is due to
the expansion of a CG-rich repeat that is difficult to reliably detect using short-read sequencing.
Rare epivariants, also called rare differentially (hyper- and hypo-) methylated regions (DMRs),
are enriched in individuals with neurodevelopmental disorders and congenital anomalies (ND-CA)
compared to controls¹⁶.

In contrast to rare DMRs, which represent discrete genomic regions with outlier 149 methylation changes, genome-wide epigenetic profiles identify a collection of distinct individual 150 CpG site methylation changes across the genome. A growing number of rare diseases exhibit 151 these methylation patterns, or episignatures, that are reproducible among individuals with 152 pathogenic variants within the same protein domain, gene, or protein complex, yielding highly 153 sensitive and specific biomarkers^{17,18}. Since episignatures in diagnostics were first clinically 154 validated and implemented with the EpiSign[™] assay in 2019¹⁹, episignatures for nearly 70 rare 155 156 diseases have been published. Episignatures provide strong evidence for genetic diagnosis, regardless of whether an underlying pathogenic DNA variant is identified, and to resolve variants 157 of uncertain significance (VUS). Episignatures have been found for neurodevelopmental 158 159 disorders where epilepsy is part of the phenotype, but the diagnostic yield for DEEs has not been 160 determined. Furthermore, how these clinically relevant episignatures might be harnessed to inform underlying disease biology and give insights into potential distinct and overlapping 161 pathogenic mechanisms among disorders is just beginning to be explored²⁰. 162

Both rare DMRs and episignatures can be detected in peripheral blood samples. Rare DMRs derived from individuals with ND-CA are recapitulated across multiple tissue types, including blood and fibroblasts¹⁶. Episignature classifiers are trained on data obtained from bloodderived DNA and are, therefore, blood-specific.

Here, we assessed rare outlier DMRs and DNA methylation episignatures in peripheral
 blood-derived DNA from 516 individuals with genetically unsolved DEEs. We report our

methylation array data processing pipeline. MethylMiner, which automates quality control. 169 170 normalization, and implementation of an algorithm that mines rare DNA methylation events¹⁴ in addition to interactive data visualization. Using a combination of short- and long-read sequencing 171 (LRS), we identify variants underlying rare epivariants and episignatures. Finally, we refine the 172 robust episignature for the DEE gene CHD2 (MIM:602119)¹⁸ to explore how clinically relevant 173 episignatures may give insights into underlying biology. For individuals with unsolved DEEs, we 174 show that rare epivariants and episignatures uncover molecular causes missed using standard 175 176 sequence-based approaches.

177

178 MATERIALS AND METHODS

179 Cohorts

Our cohorts consist of 530 affected individuals (43% female) with unsolved DEEs and 478 healthy 180 controls (46% female) (Figure S1, Table S1, Supplemental Methods), An additional 146 analytical 181 controls (60% female) were included for validation. Individuals with DEEs were recruited from 182 investigators' research and clinical programs^{21,22}. Methylation array data for healthy controls were 183 drawn from a public database²³ (n=111), an internal institutional database (n=337), and 30 184 185 unaffected parents of probands with DEEs (Supplemental Methods). Eight family members with epilepsy were studied to identify familial methylation patterns (shared rare DMRs or 186 187 episignatures). Analytical controls, including i) six individuals each with a disease-associated rare DMR, ii) 24 individuals with a pathogenic variant in a gene or CNV associated with an 188 episignature, and iii) 116 individuals with a pathogenic variant in a gene without a known 189 190 episignature, were used to validate positive and negative rare DMR and episignature findings in 191 the DEE cohort. After guality control and normalization (described below), there were 516 remaining individuals with unsolved DEEs who had undergone extensive molecular testing: 80% 192

had a gene panel, 40% microarray analysis, 76% ES, and 38% GS. Collectively, 98% had at least
one sequence-based investigation (gene panel, ES, or GS). There were also 464 healthy controls,
141 analytical controls, and eight affected family members for DNA methylation analysis. This
study was approved by the Institutional Review Board (IRB) of St. Jude Children's Research
Hospital (SJCRH). Written informed consent was provided by parents or legal guardians of
individuals with DEEs with local IRB approval from SJCRH, Austin Health (Australia), the
University of Washington (UW), and the National Institutes of Health (NIH).

200

201 Methylation Array

202 All data were derived from peripheral blood-derived DNA, except for five analytical control 203 samples used for outlier DMR analysis: saliva-derived DNA from one female individual with BSS 204 and her parent and lymphoblastoid cell line (LCL)-derived DNA from three individuals, including 205 two males and one female, with Fragile X syndrome (Coriell). These samples were used as 206 positive controls to validate the outlier analysis, and then removed from the final analysis to minimize potential cell type differences. DNA was extracted from peripheral blood samples using 207 standard protocols, with approximately 250-500ng of DNA bisulfite converted. The Illumina 208 Infinium MethylationEPIC v1.0 (850K array) bead chip arrays (processed according to the 209 210 manufacturer's protocol, Supplemental Methods) interrogate >850,000 individual CpG sites, including CpG islands, promoter regions, gene bodies, FANTOM5 enhancers, and proximal 211 ENCODE regulatory elements²⁴. 212

Of 1,162 individuals included, three individuals were run in triplicate, and 29 were run in duplicate across different batches to produce a total of 1,197 blood-derived DNA methylation array samples before quality control and processing. Each sample consisted of data for >850,000 probes that were rigorously quality-controlled for the removal of outlier samples as opposed to

outlier regions of interest. All data were combined and loaded into the R package minfi²⁵ for guality 217 control and normalization and the R package SVA²⁶ for batch correction using the ComBat 218 method²⁷. Individual CpG probes that failed (detection p>0.01) in >10% of samples and probes 219 220 overlapping with common SNPs were removed. Samples judged to be of poor guality (>1% of 221 probes that failed) and samples that were deemed outliers based on manual inspection of the principal component analysis (PC1 and PC2), using β values for probes located on chromosome 222 223 (chr) 1, were removed. We estimated blood cell type composition for six cell types (CD8T, CD4T, NK. B-cell, monocytes, and granulocytes) from β values for each sample²⁸. Samples containing 224 outlier cellular fractions defined as ≥99th percentile +2% or ≤1st percentile -2% for at least two of 225 the six cell types were also removed. Methylation array intensity values on the sex chromosomes 226 227 (X, Y) were used to infer the sample sex and compared to the clinically reported sex. Samples 228 with sex mismatch were removed. Samples were separated into inferred sex (males and females) for all downstream analyses of sex chromosomes. This guality control and filtering left 1,161 229 230 samples across 1,129 individuals (26 individuals in duplicate and three individuals in triplicate across batches) assayed by the 850K array and 833,834 probes (814,945 autosomal probes and 231 232 18,889 sex chromosome probes) (Table S1).

233

234 Identification and Annotation of Rare Epivariants

To identify outlier DMRs, we used a sliding window approach as previously described¹⁴. In brief, this algorithm employs user-defined quantile thresholds to determine outlier β values across multiple CpG sites. Per 1Kb window, at least three consecutive CpG sites must exhibit outlier β values in the same direction (hyper or hypo) for a sample compared to the rest of the cohort to be considered an outlier DMR. We considered β values above the 99.25th percentile plus 0.15 as hypermethylated, and those below the 0.75th percentile minus 0.15 as hypomethylated for analysis of the autosomes (chr1-chr22). Since samples were split into inferred sex (males and

females) for analysis of the sex chromosomes, the stringency was adjusted accordingly to 99th 242 243 plus 0.15 for hypermethylated and 1st percentile minus 0.15 for hypomethylated. DMRs were then annotated to inform functional interpretation using HOMER²⁹ and including overlap with UCSC 244 RefSeq gene bodies and promoter regions, defined as ±2Kb of the transcription start sites (TSS), 245 246 known CpG islands (CGIs), repetitive-element information (RepeatMasker and SimpleRepeats), imprinting control centers³⁰, CTCF-binding sites³¹, gene molecular function information²⁹, OMIM 247 248 phenotype³², average brain expression using bulk RNA-seq data from the GTEx Portal, and inhouse epilepsy- and candidate-gene lists to prioritize candidates but not as exclusion criteria. 249 Additionally, a recent study delineated the rare DMR landscape in the human population by 250 examining 450K methylation array data from >23,000 individuals¹⁴. Regions from those data were 251 checked against our DMRs where possible to determine the frequency at which each DMR occurs 252 253 in the population. Based on this annotation information, DMRs were prioritized by four features: 254 (1) a low or negligible population frequency; (2) a well-annotated genomic location, such as in or near known epilepsy and candidate genes; (3) recurrence in multiple individuals; and (4) manual 255 inspection of DMRs, including flanking regions. 256

257

258 Development of a DNA Methylation Array Analysis and Visualization Pipeline

259 We developed MethylMiner, a methylation array analysis pipeline tailored toward discovering rare epivariants with interactive data visualization. The pipeline requires standard input files, raw signal 260 261 idat files containing each sample's green and red channels, and a metadata sheet including sample names, sentrix IDs, reported sample sex, and sample group (if applicable). In brief, the 262 263 pipeline performs quality control and normalization as described to derive output files, including guality control reports, β values, M-values, and bigWig files for guick and convenient visualization 264 in the integrative genomics viewer (IGV)³³. The pipeline then performs the outlier DMR analysis 265 (using scripts derived from: https://github.com/AndyMSSMLab/Methylation script) based on user-266

defined quantile thresholds and outputs the DMRs and annotations into a tabulated sheet. This annotated list of DMRs is then used as input for the interactive data visualization in JupyterDash, which allows users to interact with plots for quality control metrics, DMR annotations, and DMR genomic tracks. The pipeline is hosted on our GitHub page (https://github.com/stjudebiohackathon/MethylMiner).

272

273 Validation of Outlier DMRs Using Enzymatic Methyl-Sequencing

274 We performed targeted Enzymatic Methyl-sequencing (targeted EM-seq) enriched with the Twist 275 Human methylome panel targeting 3.98M CpGs through 123 Mb of genomic content. Targeted 276 EM-seq of peripheral blood-derived DNA was used to validate a subset of outlier DMRs, including n=2 positive control DMRs (XYLT1 and FMR1) and n=29 DMRs-of-interest called amongst n=3 277 278 individuals with unsolved DEEs. EM-seg library preparation, target enrichment, and sequencing were performed using standard protocols³⁴. Reads were processed using the "nf-core/methyseq" 279 280 pipeline with the '--emseg' flag. For detailed EM-seg methods, please refer to Supplemental Methods. 281

282

283 Identification of Structural Variants with Long-Read Sequencing

We used both targeted and whole-genome LRS on the Oxford Nanopore Technologies (ONT) platform to validate rare DMRs and identify candidate disease-causing variants at or near the site of interest (Table S2A). Targeted LRS using the "read-until" function was performed on an ONT GridION using a single R9.4.1 flowcell as described previously³⁵. At least 100Kb of sequence was added to either side of the target region for capture. Libraries for GS were prepared using the ligation sequencing kit (SQK-LSK110) following the manufacturer's instructions, then loaded onto a single flowcell (FLO-PRO110, R9.4.1) on a PromethION and run for 72 hours with one wash

and reload. All data were base called using Guppy 6.3.2 (ONT) with the superior model including 5mC methylation. Reads were aligned to GRCh38/hg38 using minimap2³⁶, SNP and indel variants were called using Clair3³⁷, structural variants were called using Sniffles³⁸, SVIM³⁹, and CuteSV⁴⁰, and phasing was performed using LongPhase⁴¹. Aligned and phased bam files were visualized in IGV³³.

296

297 Episignature Testing

Data were blinded and submitted to the clinical bioinformatics laboratory [Molecular Diagnostics 298 299 Laboratory, London Health Sciences Centre (LHSC), Western University, London, Canada] 300 through a secure file transfer protocol and stored on encrypted servers. DNA methylation data for each sample were compared to clinically validated DNA methylation episignatures for all disorders 301 which are part of the EpiSign[™] v4 clinical test⁴². The reference database EpiSign[™] Knowledge 302 Database (EKD) includes thousands of clinical, peripheral blood DNA methylation profiles from 303 304 disorder-specific reference and normal controls (general population samples of various ages and racial backgrounds). Individual DNA methylation data for each individual were compared with the 305 EKD using the support vector machine (SVM) based classification algorithm for EpiSign[™] 306 disorders. A Methylation Variant Pathogenicity (MVP) score between 0 and 1 was generated to 307 308 represent the confidence of prediction for the specific disorder the SVM was trained to detect. Conversion of SVM decision values to these scores was carried out according to the Platt scaling 309 method⁴³. 310

Classification for a specific EpiSignTM disorder included a combination of MVP score, hierarchical clustering, multidimensional scaling (MDS) of an individual's methylation data relative to the disorder-specific EpiSignTM probe sets and controls. MVP score assessment had a scale with thresholds of >0.5 for positive, <0.1 negative, 0.1–0.5 inconclusive or moderate confidence.

A detailed description of this analytics protocol was described previously^{18,44}. Possible types of
 results included: positive (matching an EpiSign[™] disorder), negative (not matching any EpiSign[™]
 disorder), and inconclusive (described in detail in results).

318

319 Exome and Genome Sequencing

If sequencing data were already available for the individual on a collaborative research basis, these data were reviewed. If the data were unavailable, ES or GS was performed on peripheral blood-derived DNA using standard Illumina short-read sequencing techniques and bioinformatic approaches (Supplemental Methods). We validated potentially pathogenic variants with Sanger sequencing and confirmed sample identity and relatedness (e.g. trios) using Powerplex Short-Tandem Repeat (STR) Identification analysis.

326

327 RNA-sequencing and Gene Expression Analysis

328 RNA was extracted from dermal fibroblasts established from skin punch biopsies for Family 2 329 (n=2) and Family 3 (n=3) described in the results. RNA-seq was performed using standard Illumina short-read sequencing practices (Supplemental Methods), and the reads were processed 330 using the "nfcore/rnaseq" pipeline. Removal of the adapter sequences was performed using Trim 331 Galore!, and low-quality reads were eliminated with FastQC⁴⁵. Subsequently, reads were aligned 332 to a reference genome using the STAR aligner⁴⁶. Gene expression quantification was performed 333 334 using Salmon⁴⁷, which estimates transcript abundance. To determine gene "dropout," the OUTRIDER algorithm⁴⁸ was applied to RNA-seg data for Family 2 (proband and parent), Family 335 336 3 (proband and parent 2), and Family 3 (parent 1 and parent 2) against a publicly available dataset of n=139 fibroblast samples⁴⁹. PCA displayed no batch groupings, and genes with Fragments Per 337

Kilobase of transcript per Million mapped reads (FPKM)<1 were removed as lowly expressed
genes. Results were considered significant if they had a *padj*<0.05 and a z-score cutoff of ±2.

340

341 Refinement of a CHD2 Episignature

A total of 17 females and 12 males with genetic variants in *CHD2* and clinical features consistent with *CHD2*-epileptic encephalopathy of childhood (EEOC) were included in this expanded 850K cohort. The detailed list of genetic variants classified as pathogenic or likely pathogenic according to the American College of Medical Genetics guidelines is in Table S2B. All samples and records were deidentified.

347 Details of the methylation data analysis and episignature refinement are as previously described^{18,50-52}. Briefly, methylation signal intensities were imported into R 4.1.3 for analysis. 348 349 Normalization was performed by the Illumina normalization method with background correction using minfi²⁵. Probes located on X and Y chromosomes, known SNPs, or probes that cross-react 350 351 (as reported by Illumina) were excluded. Samples containing failed probes of more than 5% (p>0.1, calculated by the minfi package) were also removed. The genome-wide methylation 352 density of all samples was examined, and principal component analysis (PCA) was performed to 353 354 visualize the overall data structure of the batches and to identify outlier samples. All 29 samples 355 passed and were used for probe selection. The Matchlt package was used to randomly select controls, which were matched for age, sex, and array type from the EKD at the LHSC, as 356 previously described^{18,53}. The methylation level of each probe was calculated as the ratio of 357 methylated signal intensity over the sum of methylated and unmethylated signal intensities (β -358 359 values), ranging between 0 (completely unmethylated) and 1 (fully methylated). β -values were 360 then converted to M-values by logit transformation using the formula $\log_2(\beta/(1-\beta))$ to perform linear regression modeling, which was used to identify the differentially methylated probes (DMPs), via 361 the R package limma⁵⁴. The analysis was also adjusted for blood cell-type compositions, using 362

the Houseman algorithm⁵⁵. The estimated blood cell proportions were added to the model matrix of the linear models as confounding variables. The generated *p*-values were moderated using the eBayes function in the limma package and were corrected for multiple testing using the Benjamini and Hochberg (BH) method.

367 Following this, probe selection was performed in three steps. Firstly, 1000 probes were selected, which had the highest product of methylation difference means between case and 368 369 control samples and the negative of the logarithm of multiple-testing corrected p values derived from the linear modeling. Secondly, a receiver's operating characteristic (ROC) curve analysis 370 was performed, and 200 probes with the highest area under the ROC curve (AUC) were retained. 371 Lastly, probes having pair-wise Pearson's correlation coefficient greater than 0.85 within case 372 and control samples separately were removed (none of the selected 200 probes met this criteria). 373 374 This resulted in the identification of 200 DMPs. These probes were used for the construction of a 375 hierarchical clustering model using Ward's method on Euclidean distance, as well as a MDS 376 model by scaling of the pairwise Euclidean distances between samples.

377

378 Functional Annotation and Correlation of the CHD2 Episignature

379 Functional annotation and episignature cohort comparisons were performed according to our published methods⁴⁴. Briefly, to assess the percentage of DMPs shared between the CHD2 380 episignature and other neurodevelopmental conditions on the EpiSign[™] clinical classifier, 381 heatmaps and circos plots were produced. Heatmaps were plotted using the R package 382 pheatmap (version 1.0.12) and circos plots using the R package circlize (version 0.4.15)⁵⁶. To 383 determine the genomic location of the DMPs, probes were annotated in relation to CGIs and 384 genes using the R package annotatr⁵⁷ with AnnotationHub and annotations hg19 cpgs, 385 386 hg19 basicgenes, hg19 genes intergenic, and hg19 genes intronexonboundaries. CGI 387 annotations included CGI shores from 0–2Kb on either side of CGIs, CGI shelves from 2–4Kb on either side of CGIs, and inter-CGI regions encompassing all remaining regions. A chi-squared 388

389 goodness of fit test was performed in R to investigate the significance between background DMP 390 annotation distribution and the CHD2 cohort annotation distribution. P values were obtained for both annotation categories (gene and CGIs). To assess the relationship between the expanded 391 850K only CHD2 cohort and other EpiSign[™] disorders, the distance and similarities between 392 393 cohorts were analyzed using clustering methods and visualized on a tree and leaf plot. This 394 assessed the top 500 DMPs for each cohort, ranked by p-value. For cohorts with less than 500 DMPs, all DMPs were used. Tree and leaf plots, generated using the R package TreeAndLeaf⁵⁸, 395 396 illustrated additional information, including global mean methylation difference and total number of DMPs identified for each cohort. 397

398

399 Whole-Genome Bisulfite Sequencing

400 Genomic peripheral blood-derived DNA from n=3 CHD2 trios (proband and parents) and n=1 401 CHD2 singleton (proband) (total n=10 samples) were bisulfite-converted and then underwent 402 whole-genome bisulfite sequencing (WGBS) using standard Illumina short-read sequencing processing methods (Supplemental Methods). Reads were trimmed by Trim Galore! and aligned 403 to the GRCh38/hg38 human genome reference using BSMAP2.74. The methylation ratios from 404 405 BSAMP mapping results were extracted using methratio.py. Duplicated reads were removed and 406 CpG methylation from both strands was combined. The methylation ratios were also corrected according to the C/T SNP information estimated by the G/A counts on reverse strand. 407

408

409 DMR Calling of DNA Methylation Array and WGBS

We performed DMR analysis on Illumina 850K EPIC methylation array data for 16 individuals with
DEEs harboring pathogenic variants in *CHD2* compared to 18 controls. The data were normalized
using the minfi package's functional normalization algorithm⁵⁹, and we employed two independent
R packages to call DMRs, bumphunter⁶⁰ and DMRcate⁶¹. DMRs were defined as those passing

a significance threshold of p<0.05 for bumphunter and Fisher's multiple comparison P<0.05 for DMRcate. A minimum of three CpGs and mean methylation difference between CHD2 and controls of at least 5% was also required (bumphunter "cutoff" and DMRcate "betacutoff"=0.05) in either the hyper or hypo direction. For bumphunter, smoothing was used, and the number of permutations for each condition was set to B=1000. For DMRcate, default settings were used, and the Gaussian kernel bandwidth for smoothed-function estimation was set to λ =1000, meaning that significant CpGs further than 1000 nucleotides were in separate DMRs.

421 The methylCall data from WGBS, which consists of the total number of reads covered for 422 each CpG site and the number of methylated C's at each CpG site, was used for calling DMRs between four individuals with DEEs caused by pathogenic CHD2 variants and six unaffected 423 parents. Firstly, CpG sites with less than 10X coverage and those on the sex chromosomes were 424 425 removed. DMRs were called from WGBS methylCall data using two independent R packages, DMRcate⁶² and DSS⁶³. DMRcate identifies and ranks the most differentially methylated regions 426 427 across the genome, while DSS detects differentially methylated loci or regions from WGBS. For DMRcate, the scaling factor for bandwidth "C" was set to 50, as recommended for WGBS. DSS 428 429 was run with default parameters. DMRs were defined by each algorithm (with smoothing) as regions of a minimum of five CpGs with significance (Fisher's multiple comparison P value <0.05) 430 and minimum methylation differences of 5% in either the hyper or hypo direction (DSS "delta" and 431 DMRcate "betacutoff"=0.05) between cases and controls. 432

The genomic locations of output DMR calls were intersected between both callers requiring a minimum overlap of 50bp in the same direction to reduce the false positive rate. This resulted in high-confidence list of DMRs predicted by two independent callers for array (bumphunter and DMRcate) and WGBS (DMRcate and DSS). The methylation difference between CHD2 and control was averaged between both callers for the final DMR list. DMRs were segmented by mean methylation difference between CHD2 and control (5%, 10%, 15%, and 20%) for visualization and annotation with CpG elements (islands, shores, shelves) and gene regions

(1-5Kb upstream TSS, promoters as <1Kb upstream TSS, 5'UTRs, exons, introns, and 3'UTRs)
using annotator⁵⁷. To get adequate CpG element counting (i.e. a DMR spanning both a shore and
shelf would not get counted twice), CpG annotations were adjusted for DMR size by calculating
representation across CpG elements as a fraction of the total DMR length.

444

445 **<u>RESULTS</u>**

446 **Discovery and Validation of DMRs in Unsolved DEEs**

To determine the ability of our analysis pipeline to robustly detect rare, outlier DMRs, we included 447 DNA from six positive controls with genetic diseases: three individuals with heterozygous or 448 449 homozygous hypermethylation of XYLT1, and three individuals (two males and one female) with hypermethylation of *FMR1*. The outlier DMR analysis detected both rare DMRs (Figure S2, Table 450 451 S3A). Additionally, we identified an XYLT1 heterozygous hypermethylation carrier in our DEE cohort. Targeted X-chromosome analysis in males identified complete methylation at the FMR1 452 locus in both Fragile X males compared to the remaining cohort, all of which were completely 453 454 unmethylated at FMR1. FMR1 hypermethylation was also higher (~75%) in the Fragile X female sample compared to the other females with 25-50% methylation, likely due to random X-455 inactivation. Thus, our methylation array analysis approach detects outlier DMRs at known 456 457 disease loci for the autosomes and sex chromosomes.

Next, we assessed outlier DMRs in our cohort of 1,124 individuals (516 unsolved DEE) across 1,156 array samples. We predicted n=2,140 total DMRs for the autosomes, n=59 DMRs for males on chromosome X, n=42 DMRs for females on chromosome X, and no DMRs on chromosome Y (Table S3B, S3D, S3F). After accounting for DMRs overlapping across samples (≥50% probe overlap in the same direction of DNA methylation hyper- or hypo-methylation), we derived n=1,540 unique DMRs for the autosomes (917 hyper, 623 hypo), n=45 for males on chrX (26 hyper, 19 hypo), and n=34 for females on chrX (20 hyper, 14 hypo) (Table S3C, S3E, S3G).

465 Of the samples with one or more outlier DMRs, the majority had only a single outlier DMR (Figure466 S3).

To determine the robustness of our DMR calling algorithm, we (i) assessed the 467 reproducibility of DMR calls in a subset of samples and (ii) performed validation of DMRs using 468 469 targeted EM-seg (Supplemental Methods). Using replicate array data for 29 individuals, we found 470 that 80% of DMRs were replicated across different batches for an individual (Supplemental Methods). We then used targeted EM-seq, a non-bisulfite approach, to validate a subset of DMRs. 471 472 We confirmed that our positive control DMRs (XYLT1 and FMR1) could be detected in the targeted EM-seq data (Figure S4). We then validated 30 outlier DMRs by targeted EM-seq in four 473 individuals with unsolved DEEs (Figure S5 and S6). In addition to DMR validation, targeted EM-474 seq provides much higher resolution of the extent of differential methylation than the methylation 475 476 array (e.g. >100 methylated CpG sites for the XYLT1 DMR by targeted EM-seg compared to eight 477 representative probes on array; Table S4). Thus, we detected and validated outlier DMRs at higher resolution using an orthogonal approach. 478

479

480 **Rare Outlier DMRs in Unsolved DEEs**

We narrowed down outlier DMR calls for individuals with unsolved DEEs to determine high-priority candidates for further study based on DMR recurrence across multiple individuals, population frequency¹⁴, functional annotations (Methods), and manual inspection of DMR plots for each DMR. We identified 11 individuals with unsolved DEEs with one or more rare, potentially diseaseassociated DMRs and performed follow-up studies (Table 1, Table S2A). One individual had multiple DMRs due to a balanced translocation between chrX and chr13, four individuals had a DMR due to expanded CG-rich repeats, and six individuals had DMRs due to underlying CNVs.

488

489 Rare Outlier DMR Analysis Detects Hypermethylation of chr13 Due to X;13 Translocation

490 One female with the DEE syndrome, epilepsy of infancy with migrating focal seizures (EIMFS), had 27 rare outlier hypermethylated DMRs across chr13 (Figure 1A, Figure S7), none of which 491 were present in >23,000 controls¹⁴. The DMRs were replicated on a second, independent 492 493 methylation array from the same individual and validated using targeted EM-seg (Figure S6). 494 Methylation array analysis of both parents revealed that all rare hypermethylated DMRs occurred de novo in the proband (Figure 1B). Whole-genome ONT long-read sequencing also confirmed 495 the hypermethylated DMRs and identified a balanced translocation between chrX and chr13 496 497 (Figure 1C), annotated as 46,XX,t(X;13)(q28;q14.2). The translocation provides a mechanism whereby random X-inactivation induces hypermethylation on the portion of chr13g attached to the 498 large piece of the X chromosome. The translocation breakpoints were confirmed by PCR and 499 500 Sanger sequencing of peripheral blood-derived DNA as chrX:152,092,342 to chr13:47,005,269 501 and chr13:47,005,271 to chrX:152,092,344 (GRCh38/hg38). Parental methylation studies and short-read GS confirmed that the translocation occurred de novo. The translocation is likely 502 503 causative in this individual given the de novo occurrence, absence of clearly pathogenic sequence 504 variants by trio sequence (Table S5), and report of a similar translocation in a female individual with intellectual disability and bilateral retinoblastoma⁶⁴. 505

506

507 Rare Outlier DMR Analysis Detects Hypermethylation Caused by Underlying Triplet Repeat 508 Expansions

509 We detected two individuals with unsolved DEEs and one control individual with hypermethylation 510 spanning the 5'UTR and intron 1 of the Casein kinase 1 isoform epsilon (*CSNK1E*, MIM:600863, 511 Figure 2A) gene. Although present in one control and reported in 6/23,116 controls¹⁴, an individual 512 with DEE and probable haploinsufficiency due to a *de novo* splicing variant (c.885+1G>A) in

CSNK1E has been reported⁶⁵, suggesting further study is warranted to determine if variation in 513 514 this gene causes DEE. Segregation analysis revealed that the hypermethylation in one proband 515 was inherited (Family 1, Figure S8), whereas the other arose *de novo* (Family 2). After validation 516 of hypermethylation with targeted EM-seq for both probands (Figure S5), long-read sequencing 517 of the proband (whole-genome) and parent (targeted) from Family 1 confirmed the presence of an expanded CGG motif in both (Figure 2B), as previously reported in individuals with 518 519 hypermethylation of CSNK1E at fragile site FRA22A and reduced expression in lymphoblastoid cells¹⁴. Through GeneMatcher⁶⁶, we identified Family 3 consisting of a proband with the same 520 CSNK1E hypermethylated DMR inherited from his parent, who is mildly affected by learning, 521 speech, and sleep difficulties (Supplemental Phenotype data). Expression analysis in available 522 fibroblasts from Families 2 and 3 showed that individuals with CSNK1E hypermethylation had 523 524 decreased expression of CSNK1E compared to hypermethylation-negative controls (Figure 2C). algorithm⁴⁸ OUTRIDER 525 Analysis using the confirmed "drop-out" of CSNK1E (ENSG00000213923) expression compared to publicly available fibroblast controls⁴⁹ (Figure 2C, 526 Figure S9). Thus, we report 3 individuals with unsolved DEEs harboring inherited and de novo 527 528 CSNK1E hypermethylation due to an underlying repeat expansion (n=4 LRS) that leads to 529 approximately 50% reduction in CSNK1E expression (n=3 RNA-seq drop-out). No other candidate gene variants for these 3 probands were found by trio GS analysis. However, due to 530 531 finding this abnormality in seemingly unaffected individuals, one control and one parent (Family 1) in our cohort and others¹⁴, further work is required to determine whether variations in CSNK1E 532 cause or contribute to the DEEs. 533

A male individual with unsolved DEE displayed inherited hypermethylation of the *DIP2B* (MIM:611379) promoter region and exon 1 (Figure S10), which is due to an underlying CGGrepeat expansion and fragile site FRA12A⁶⁷. Loss of *DIP2B* is associated with an autosomal

dominant neurodevelopmental disorder (NDD) with variable penetrance, including a *DIP2B* repeat
 expansion in an individual with epilepsy⁶⁷.

We detected a rare hypermethylated DMR on the X chromosome in exon 1 of an 539 uncharacterized gene (BCLAF3/CXorf23) in a male with unsolved DEE (Figure S10), that was 540 absent in >23,000 unaffected controls (>8,000 males)¹⁴. We validated hypermethylation using 541 targeted EM-seg (Figure S5), and ONT long-read sequencing of the proband and his parent 542 revealed a novel CGG repeat expansion in the proband (~2,500-3,000bp, Figure S11) inherited 543 544 from his parent, who had a smaller expansion (~1,700-1,900bp). LRS and standard X-inactivation studies⁶⁸ show that the parent has skewed X-inactivation (Table S6) of the allele with the 545 expansion, which explains why outlier hypermethylation is not detected from her methylation array 546 data. There are no other candidate variants for the proband's DEE by trio GS. Collectively, these 547 548 results highlight the detection of repeat-expansion-associated loci based on outlier DMR analysis 549 of DNA methylation array in individuals with unsolved DEEs.

550

551 Rare Outlier DMR Analysis Detects Copy Number Variants

Six individuals displayed DMRs that were found to be due to underlying CNVs. One control and an individual with unsolved DEE had ~10-15 hypomethylated DMRs along chr2 spanning \geq 144Kb (Figure S12A). Short and long-read sequencing analysis revealed this "DMR" was due to a homozygous ~182Kb deletion encompassing outlier DMRs (Figure S12C). Segregation testing found that the proband inherited the deletion from both parents, who were heterozygous carriers. The CNV was also found on DNA methylation array using the R tool conumee⁶⁹ (Figure S12B).

558 Four individuals with unsolved DEEs and one control had a 686bp hypomethylated DMR 559 in intron 2 of the gene *LINGO1* (MIM:609791). DNA methylation array analysis for a proband's 560 parent found that the hypomethylation was at least in part inherited, and short and long-read

sequencing revealed that hypomethylation was caused by an underlying ~4Kb inherited deletion(Figure S13).

Another individual with unsolved DEE had hypermethylation in the 5'UTR of 563 CFAP36/CCDC104 (Figure S14A), which was not present in >23,000 controls¹⁴. DNA methylation 564 565 array analysis of both parents indicated it was inherited (Figure S14B), and targeted ONT longread sequencing revealed a ~500Kb tandem duplication from chr2:55,034,228-55,536,971 566 (GRCh38/hg38). Collectively, these results indicate that outlier DNA methylation can be due to 567 underlying CNVs and that the 850K methylation array may not have sufficient coverage to detect 568 569 smaller CNVs. Due to the high population frequencies and inheritance status of the CNVs we found, we determined they are unlikely to contribute to the individuals' phenotypes. Still, these 570 findings illuminate ways in which detected DNA methylation changes are influenced by underlying 571 572 DNA variation.

573

574 Episignature Screening Validates Pathogenicity of Genetic Diagnoses and Resolves 575 Variants of Uncertain Significance

We next performed episignature analysis, using the EpiSign[™] v4 classifier, including 70 576 577 conditions associated with 96 genes/genomic regions (Figure 3). To validate our approach, we included several individuals with causal variants in episionature genes or CNVs and an individual 578 579 with a VUS. These included sixteen individuals with variants in CHD2 (n=15 pathogenic, n=1 VUS) and one individual each with a pathogenic variant in KDM5C, SETD1B, KMT2A, or 580 SMARCA2 (Table S2B). We also included two individuals with CNVs, including chr17p11.2 581 582 deletion and duplication. Fifteen of the individuals with variants in CHD2 were positive for the epileptic encephalopathy of childhood (EEOC) episignature¹⁸, also known as the developmental 583 and epileptic encephalopathy 94 (DEE94) episignature. However, one individual with a VUS in 584

585 *CHD2* was negative for the episignature, and in combination with other clinical evidence the VUS 586 was reclassified as likely benign (Supplemental Phenotype data). The individuals with variants in 587 *KDM5C* (MIM:314690), *SETD1B* (MIM:611055), *KMT2A* (MIM:159555), and *SMARCA2* 588 (MIM:600014) were all positive for the episignatures associated with their disorders. While these 589 individuals were considered solved before episignature screening, the finding was used to support 590 the genetic diagnosis of the individual with a *KDM5C* variant.

Additionally, we identified two individuals with inconclusive results for episignatures 591 592 despite definitive genetic and clinical findings for the associated syndromes. Inconclusive findings 593 are caused by methylation profiles that partially overlap existing signatures but are not a definitive match. This included an individual with a 17p11.2 deletion inconclusive for the Smith-Magenis 594 syndrome episignature (SMS del) and a female individual with a 17p11.2 duplication inconclusive 595 596 for the Potocki-Lupski syndrome episignature (PTLS, Figure S15). In each case, the inconclusive 597 episignature finding is concordant with the genetic diagnosis but yields an inconclusive result potentially attributable to variability introduced by differential CNV breakpoints. Because of this 598 and other factors, inconclusive EpiSign[™] results are reported with the caveat that further follow-599 up or investigation may be warranted if there is a clinical phenotype consistent with the 600 601 inconclusive episignature in question.

602

603 Episignature Screening Solves Genetically Unsolved DEEs

We then tested our cohort of 516 individuals with unsolved DEEs for 70 clinically validated episignatures, leading to a likely diagnosis in five individuals (Table 2). All methylation variant pathogenicity (MVP) scores for episignatures and detailed genomic variant information are in Table S2C. Two unrelated individuals with unsolved DEEs were positive for the KGB syndrome episignature (KGBS_MRD23) caused by pathogenic variants in *ANKRD11* (Figures S16 and

609 S17). Exome or genome sequencing analysis revealed *de novo* pathogenic stop-gain variants in both individuals, and phenotypes for each individual are consistent with the diagnosis 610 (Supplemental Phenotype data). One proband had affected siblings and family members (n=8, 611 612 Figure S17). However, none harbored the ANKRD11 episignature and neither affected sibling 613 harbored the variant, indicating that there is likely a different explanation for this familial epilepsy. 614 One individual with unsolved DEE was positive for the episignature associated with SETD1B 615 (Figure S18). Exome sequencing revealed a pathogenic stop-gain variant in SETD1B. Another 616 individual with unsolved DEE harbored the episignature for TET3 and had an inherited pathogenic stop-gain variant in TET3 on GS (Figure S19). This remains the likely cause of the individual's 617 DEE as the parent has a milder phenotype including macrocephaly and learning difficulties 618 (Supplemental Phenotype data). One male individual with unsolved DEE was positive for the 619 620 UBE2A episignature (Figure S20). Through exome sequencing, we identified a predicted 621 damaging inherited missense variant absent in gnomAD (c.376G>A, p.Ala126Thr). Although the 622 variant does not reach likely pathogenic classification using existing ACMG criteria, the prediction scores (REVEL=.776, CADD=26.4, and PolyPhen-2=1.00) support pathogenicity; the variant is 623 624 inherited in an X-linked intellectual disability disorder; and the individual shares multiple phenotypic features with UBE2A disorder. Thus, the variant has been determined to be the most 625 likely genetic cause of disease. 626

Of the high-confidence episignature findings, only one individual had an established genetic diagnosis in another gene. This individual harbored a *de novo* variant in *PTEN* with a consistent phenotype of macrocephaly and focal epilepsy but also had the episignature for *KDM2B*. Further analysis identified an inherited missense variant in *KDM2B*. We performed methylation array analysis for the unaffected parent who also harbored the *KDM2B* episignature. This variant is predicted to be likely pathogenic (LP) by ACMG criteria due to its putative effect on splicing regulation, though assessment of this variant with SpliceAI predicts that it does not have

a high likelihood of affecting splicing (Δ score for Donor Gain:0.01). When this criterion is taken away, the designation of LP is reduced to a VUS; other computational predictors assess the impact to be uncertain (REVEL=0.517). Thus, while it is unlikely that this *KDM2B* variant explains the individual's phenotype, it still represents an underlying DNA change detected through episignature screening. Collectively, we have identified positive episignatures and causal genetic etiologies in five previously unsolved individuals with DEEs through episignature screening.

An additional 40 individuals with DEEs (80% unsolved) and nine controls had inconclusive 640 results for episignatures (Figure S20). Of the individuals with DEEs, 4/40 were run across multiple 641 642 methylation array batches. Three individuals did not reproduce their inconclusive episignature result in the other sample(s). While one individual's inconclusive result did replicate across the 643 different batches, no pathogenic variants were found by GS in the associated genes(s). Of all the 644 645 individuals with available sequencing data (n=27), none harbored pathogenic variants in the 646 genes associated with episignature findings. While some had overlapping clinical features, most were discordant with the described phenotypes for their inconclusive episignature finding. 647 Additional follow-up will be required to determine whether these inconclusive results are due to 648 649 array artifacts or have underlying biological or disease-associated meaning. If technical artifacts 650 are ruled out, an inconclusive result may be caused by episignatures in other genes that are yet to be defined and trained against for specificity of the classifier. 651

652

653 Redefining the CHD2 Episignature on the 850K EPIC Array

While episignatures are proven to be clinically useful for diagnosis, little work has been done to investigate how episignatures may inform disease biology by studying DMRs that may impact gene expression. Here, we performed refinement and in-depth analysis of the episignature for the DEE gene *CHD2*. The CHD2 episignature was originally derived using overlapping 450K and

850K DNA methylation array probes representing individual CpG sites in n=9 individuals with pathogenic *CHD2* variants¹⁸. We refer to this signature as the CHD2 450K episignature (Figure 4A upper, Figure S21A, Table S7). Here, we refine the CHD2 episignature exclusively on 850K EPIC methylation array probes with data from a cohort of n=29 individuals with pathogenic *CHD2* variants (Figure 4A lower, Figure S21B, Table S7). We refer to this signature as the CHD2 850K episignature. Of the 200 probes included in the CHD2 850K episignature, 79/200 are specific to the 850K EPIC array.

665

666 Comparison of the CHD2 Episignature to 55 Other Clinically Validated Episignatures

667 We then compared the CHD2 450K and 850K episignatures to 55 other NDD episignatures (57 total including CHD2)²⁰ by examining shared probes (Figure 4B, Figure S22), Euclidean clustering 668 (Figure 4C), probe mean methylation differences (Figure S23), and functional annotations (Figure 669 670 S24). As expected, the CHD2 850K episignature shares the most probe overlap with the CHD2 671 450K episignature (86/200 or 43%, Figure 4B, Figure S22). Euclidean clustering was used to 672 examine the relatedness of the episignatures by probe overlap and directionality. The CHD2 850K episignature shares the closest branchpoint with the MRXSCJ episignature for KDM5C of which 673 it shares 7% of its top 500 DMPs. Collectively, both 450K and 850K episignatures do not share 674 675 immediate branches (other than the primary branchpoint) with many other episignatures. This may indicate different sets of predominant pathways underlying CHD2 pathophysiology compared 676 677 to the other episignatures. Additionally, the CHD2 850K episignature represents more hypermethylated regions than the CHD2 450K episignature, as depicted by the mean methylation 678 679 differences in Figure 4C and Figure S23. We also performed functional annotation of episignature 680 probes for CpG characteristics and gene regions in relation to the 55 other NDD episignatures (Figure S24). We found that both CHD2 850K and 450K DMPs map to predominately the coding 681 regions of genes (46% and 41%, respectively) with a significant difference in the distribution of 682

DMPs in these regions compared with the background probe distribution (P<9.06 x10⁻⁶⁹ and P<2.02 x10⁻⁷⁹, respectively). Though the CHD2 850K episignature represents a higher portion of interCGI regions compared with the 450K episignature (43% vs. 31%, respectively), both are enriched in interCGI regions relative to background probe distribution (P<2.26x10⁻¹²¹ and P<9.17x10⁻¹⁴⁴).

688

689 The CHD2 Episignature is Associated with Differentially Methylated Regions

690 Since CHD2 encodes a chromatin remodeler that has been shown to regulate gene expression^{70,71}, we investigated whether individual episignature probes are contained within larger 691 692 DMRs between cases and controls. DMRs could potentially provide a link to downstream gene expression. We first investigated DMRs in an unbiased genome-wide manner by calling DMRs 693 694 from the 850K DNA methylation array data (n=16 CHD2, n=18 controls) using bumphunter and 695 DMRcate. We predicted 1,684 DMRs from bumphunter and 963 DMRs from DMRcate. These 696 DMRs were intersected, requiring an overlap in the same direction (hyper/hypo) of at least 50bp, 697 to derive a high-confidence DMR list of 712 overlapping regions (349 hyper, 363 hypo). Representative images of these DMRs are shown in Figure S25. These DMRs directly coincide 698 with 86/200 (43%) CHD2 450K episignature probes and an increased 90/200 (45%) CHD2 850K 699 700 episignature probes (Figure S26, Table S8). Thus, the CHD2 episignature is characterized by DMRs, and this overlap increases by four probes for the CHD2 850K episignature. 701

702

Increased CpG Resolution and Genomic Coverage of Differentially Methylated Regions Using Whole Genome-Bisulfite Sequencing

Due to limited genomic coverage, DNA methylation arrays can be skewed in their representation of CpGs across the genome, as evidenced by their tendency to bias gene set analyses⁷². To better understand the DMR landscape of *CHD2* and investigate DMRs at higher CpG resolution,

708 we performed WGBS with coverage of >20,000,000 CpGs on three CHD2 trios and one singleton. 709 We derived 11,019 DMRs from DSS, 4,078 DMRs from DMRcate, and 3,665 DMRs that overlap between both callers (2420 hyper, 1235 hypo). To determine the robustness of this approach, we 710 711 manually inspected DMRs with a methylation difference of at least 20% (n=207 DMRs, 146 hyper, 712 61 hypo) by examining the reads in all 3 trios in IGV and confirmed 169/207 DMRs, yielding a 713 true call rate of 81.6%. Representative DMRs called from WGBS are shown in Figure S27. We 714 then investigated the overlap of episignature probes with the WGBS DMRs with a methylation 715 difference of at least 5% and found direct overlap with 76/200 (38%) CHD2 450K episignature probes and an increased 94/200 (47%) CHD2 850K episignature probes (Figure 4D, Figure S26). 716 Thus, considering the increased genomic coverage afforded by WGBS and increased DMRs, it 717 718 is unsurprising that a higher proportion of CHD2 850K episignature probes overlap with DMRs 719 (Figure S26, Table S8). Notably, for nearly all probes found within DMRs, those DMRs could be 720 better visualized from the WGBS data due to the lack of probe coverage on the array. Thus, we have confirmed using an orthogonal approach with higher CpG coverage that the CHD2 721 episignature is characterized by DMRs. 722

723 We further investigated DMR calls by functionally annotating them using the annotatr. We 724 first examined the representation of CpG islands, CpG shores, CpG shelves, and interCpG Island (interCGI) regions for DMRs (Figure S28). We find that most DMRs called exclusively from WGBS 725 are located at interCGI regions compared to DMRs called from the array or overlap of both, likely 726 727 due to the bias of gene-enriched regions on the array compared with increased genomic coverage 728 of WGBS. We also annotated DMRs with gene annotations (Figure S29) and found similar patterns across DMRs called by the 850K array, WGBS, or both, especially for DMRs called with 729 a methylation difference of at least 5% between CHD2 and controls. Notably, we show how the 730 global CHD2 episignature is characterized by DMRs (Figure S30) that correspond to gene 731 732 regulatory regions and therefore, likely affect underlying disease biology.

733

734 **DISCUSSION**

735 A major challenge in rare disease genetics is determining molecular causes in unsolved cases. Even if ES or comprehensive GS of trios identifies all de novo and recessively inherited coding 736 737 and noncoding variants, prioritizing and functionally interpreting candidate variants is challenging. 738 In the case of the DEEs, this difficulty is further compounded by immense phenotypic and genetic 739 heterogeneity. Genome-wide DNA methylation analysis represents an innovative approach to 740 discovering genetic etiologies by investigating rare DMRs and screening for DNA methylation 741 signatures. Notably, rare DMRs and episignatures can be assessed with cost-effective, highthroughput DNA methylation arrays using blood-derived DNA. Here, we performed genome-wide 742 DNA methylation analysis on 516 individuals with unsolved DEEs and identified causal or 743 744 candidate etiologies in 10 individuals: five from rare DMR analysis (Table 1) and five from episignature screening (Table 2). Thus, the diagnostic yield of genome-wide methylation analysis 745 in individuals with unsolved DEEs is nearly 2%, similar to the added diagnostic yield of GS after 746 ES or gene panel^{73,74}. A study of unsolved ND-CA showed a similar 2-3% increase in diagnostic 747 yield using episignature analysis⁵². 748

749 We have performed rare outlier DMR analysis of methylation array data for a cohort of 750 individuals with unsolved DEEs and uncovered various underlying DNA variants using ONT longread sequencing. These include a X:13 translocation, CGG repeat expansions, and copy number 751 752 variants. We first validated a subset of outlier DMRs using targeted EM-seq enriched for 3.98M CpGs, a highly effective bisulfite-free, enzyme-based conversion method for detecting CpG 753 754 methylation by sequencing. Targeted EM-seq has several advantages to bisulfite-based array 755 approaches, including minimizing DNA damage, lowering input requirements (picograms of DNA), and detecting more CpGs³⁴. We found that all DMRs were confirmed using the EM-seg approach. 756 757 and the greater number of CpGs detected compared to the methylation array afforded higher

resolution to interpret DMRs. Future high-throughput DNA methylation analyses could consider
 using EM-seq for validation or discovery.

We report an individual with 27 outlier hypermethylation events along chr13q detected through the rare DMR analysis. Using ONT whole-genome long-read sequencing, we identified a *de novo* X;13 translocation showing that the hypermethylation identified the likely cause of disease. This discovery was enabled without the need for live cellular material, which is typically required by classical cytogenetics approaches. This child passed away in infancy due to the severity of the disease, and this approach provided a diagnosis postmortem using banked genomic material.

767 We also found that several individuals displayed hypermethylation of loci associated with known or novel CG-rich repeat expansions. These regions include the 5'UTR and intron 1 of the 768 769 epilepsy candidate gene CSNK1E, the 5'UTR of the neurodevelopmental disorder gene DIP2B, and the 5'UTR of the uncharacterized gene BCLAF3. We report the occurrence of 770 hypermethylation, a CGG repeat expansion, and reduced expression of CSNK1E among three 771 772 unrelated individuals with unsolved DEEs and a mildly affected parent. CSNK1E has been implicated in the circadian rhythm^{75,76}, and variation causes a familial advanced sleep phase 773 syndrome (FASPS)⁷⁷. Variation also produces a rapid eye movement phenotype in a knockout 774 mouse model⁷⁸. Interestingly, all our probands with DEEs and the mildly affected parent with 775 776 CSNK1E hypermethylation and a repeat expansion report sleep-related phenotypes 777 (Supplemental Phenotype data). Our results indicate that there is an enrichment of CSNK1E 778 hypermethylation in individuals with DEE compared to controls in our cohort combined with those previously reported¹⁴ (Fisher's Exact *P*=0.0185), suggesting that further studies to determine if 779 780 CSNK1E variation contributes to DEEs are warranted.

781 One male proband with unsolved DEE displayed *de novo* outlier hypermethylation in a 782 region annotated as intergenic on the GRCh37/hg19 genome build and at the 5'UTR of *BCLAF3*

783 on the GRCh38/hg38 genome build. Using ONT long-read sequencing, we discovered a novel 784 CGG repeat expansion in exon 1 of BCLAF3 in this proband inherited from his unaffected parent. The parent's long-read data displayed skewed X-inactivation against the expanded allele, and 785 786 this was confirmed to be more global using an enzyme-based DNA methylation assay to profile the AR and HUMARA loci (Table S6)⁶⁸. Skewed X-inactivation may explain why the parent does 787 788 not have a detectable DNA methylation abnormality at this locus and could provide a mechanism 789 to circumvent any functional consequences of the BCLAF3 abnormality. While BCLAF3 has been previously predicted to be a potential disorder-associated gene on chrX⁷⁹, little is known about its 790 function or disease associations. Thus, further work is needed to investigate whether this 791 abnormality is present in other individuals and if loss of this gene on chrX in males could cause a 792 793 DEE.

We performed episignature screening of our unsolved DEE cohort using the EpiSignTM v4 794 795 classifier, which contains 90 episignatures representing 70 disorders encompassing 96 genes/genomic regions. We found six individuals with unsolved DEEs harbored positive 796 797 episignatures concordant with their phenotypes. We reviewed or reanalyzed available or newly 798 generated ES or GS data and identified pathogenic variants in the episignature-associated genes 799 in 5/6 individuals. In the individual with a pathogenic SETD1B variant, one parent was unavailable 800 for genetic testing to segregate the sequence variant. Thus, the positive episignature finding 801 provided supportive information for genetic diagnosis in lieu of inheritance data. Episignatures 802 can serve to screen for disorders that have broad, overlapping phenotypes and identify individuals 803 who may not have the classical features of a specific neurodevelopmental syndrome or DEE. For instance, most DEEs have a phenotypic spectrum, so individuals with different etiology, 804 developmental trajectories, or subtle dysmorphic features may escape diagnosis until a molecular 805 806 etiology is found.

The top 27 most implicated genetic causes of DEEs explain 80% of DEEs⁷. However, only 807 808 1/27 genes (CHD2) has a clinically validated episignature. Like CHD2, 58/59 genes with robust episignatures localize to the nucleus and are associated with DNA binding, transcriptional 809 810 regulation, and histone interactions. Since DNA methylation occurs in the nucleus, most genes 811 for which episignatures have been derived are directly or indirectly involved in the epigenetic and transcriptional machinery. Whereas the top 27 DEE genes are associated with a range of cellular 812 813 processes⁵, only a minority are associated with direct DNA interactions, and only 10 of the top 27 most frequent DEE genes are annotated to localize to the nucleus at least partially. The only gene 814 with a clinically validated episignature not involved in any nuclear activity is SLC32A1, which 815 816 encodes solute carrier family 32 member 1 (SLC32A1, MIM:616440) responsible for inhibitory neurotransmission, and variants in this gene cause a DEE⁸⁰. Unfortunately, SLC32A1 is not 817 818 among the most common ~60 DEE genes. Therefore, the diagnostic utility of episignatures for 819 DEEs would increase when we can confidently derive episignatures for more DEE genes, such 820 as ion channel, synaptic transmission, and metabolic genes.

Episignature derivation is further complicated by the existence of variant-specific 821 episignatures that exist for a subgroup of variants within a gene (e.g. SMARCA2^{50,81}) or a set of 822 823 common genes within similar pathways (e.g.Coffin-Siris syndrome episignature, due to variants 824 in ARID1A (MIM: 603024), ARID1B (MIM:614556), SMARCB1 (MIM:601607), and SMARCA4 (MIM:603254), and SOX11 (MIM:600898)⁵⁰. Thus, there is not only a need to derive episignatures 825 826 for more epilepsy-related genes but also to analyze variants for testing based on variant type (i.e. 827 missense, nonsense) and protein domain, which may segregate with phenotypes. For instance, our cohort included two females with solved DEEs and pathogenic truncating variants in the 828 SMC1A gene located on chromosome X. Neither had a positive episignature for SMC1A for 829 Cornelia de Lange syndrome (CdLS), which is usually due to missense or in-frame small indels 830 831 proposed to have a dominant negative effect. Truncating, loss-of-function variants, however, are

832 found exclusively in girls with DEEs. The difference in underlying disease mechanism likely 833 impacts the composition of the distinct probe sets contained within the episignatures. Discordant or unusual findings like this example underscore additional considerations when deriving and 834 interpreting episignatures. We came across five individuals reported as male whose methylation 835 836 pattern on the X chromosome suggested two X chromosomes. Of 2/5 of these individuals who 837 had LRS, a genotype of XXY was confirmed, which is consistent with a diagnosis of Klinefelter 838 syndrome. More unexpected and incidental findings will arise as a greater number of 839 episignatures are derived, and methylation testing becomes more routine.

840 Episignatures for many epilepsy-related genes are currently in development. As more episignatures are clinically validated, re-analysis of previously generated methylation array data 841 from unsolved individuals will identify pathogenic findings, akin to re-analysis of exome 842 sequencing data for new epilepsy genes years after initial sequencing was performed⁸². We found 843 844 that episignature analysis was useful for clarifying VUSs, including an individual annotated as solved for CHD2 displaying a VUS, which was re-assessed as benign based on a negative CHD2 845 episignature result. We anticipate that episignatures will also be useful for interpreting the impact 846 847 of noncoding variants.

848 There are additional considerations when determining the utility of DNA methylation 849 analysis for the molecular diagnosis of individuals with DEEs. Firstly, the diagnostic utility will vary 850 depending on when the individual receives the test relative to other genetic testing modalities. In 851 our study, we analyzed DNA from individuals with DEEs who had remained unsolved after undergoing extensive genetic testing, including gene panels, microarrays, exome, and genome 852 853 sequencing. As DNA methylation testing becomes increasingly accessible to newly diagnosed individuals with DEEs and as the number of epilepsy-relevant genes with robust episignatures 854 grows, the utility of DNA methylation analysis in unsolved DEEs may increase and guide which 855 856 regions should be sequenced to identify causal variants.

857 DNA methylation information can be readily assessed from both ONT long-read 858 sequencing and PacBio long-read sequencing data. Therefore, when long-read sequencing 859 becomes more available, there is potential for an "all-in-one" approach to genetic testing whereby 860 individuals can simultaneously be assessed for sequence variants, structural abnormalities, and 861 rare DNA methylation changes. While it is advantageous to study rare DMRs and their potential underlying DNA defects using the same technology, applying episignatures to long-read 862 863 sequencing data is uncertain and may require new computational approaches to re-derive and 864 validate episignatures on each platform. As long-read sequencing produces far more data than arrays (>20,000,000 CpGs versus ~850,000 CpGs), this will offer an opportunity to interrogate 865 DNA methylation more broadly and deeply. 866

As advances in sequencing technologies allow DNA methylation datasets to get larger, 867 868 there will be a need to analyze comparative data from controls to generate population-level 869 reference information. For our DMR analysis, we leveraged 450K DNA methylation array outlier DMR calls generated from peripheral blood-derived DNA for >23,000 control individuals¹⁴. Where 870 871 possible, we used these data to approximate population frequencies for the DMRs we derived. 872 However, this reference information is not available for 850K exclusive DMRs or whole-genome 873 sequencing DMRs. Thus, interpreting DNA methylation data for unsolved DEEs and other 874 unsolved genetic disorders will improve as we understand more of the methylome, including regions that were only recently resolved on the T2T genome build⁸³, using appropriate reference 875 876 datasets from diverse populations.

While episignatures provide a robust readout of the genetic etiology, they are composed of individual array probes representing singular CpG sites that may not contribute to understanding the underlying disease mechanism. Given that *CHD2* is the most frequent DEE genes with a robust episignature and has a biological role as a chromatin remodeler, we were interested to use the episignature to understand how DNA methylation relates to underlying *CHD2*

882 pathophysiology. First, we re-defined the episignature on exclusively 850K array probes with an 883 increased sample size from n=9 to n=29 individuals with CHD2 pathogenic variants. Using DNA methylation array and WGBS, we show that the CHD2 episignature is associated with DMRs 884 between cases and controls. In a recent study, investigators derived DMRs for individuals with 885 886 pathogenic HNRNPU (MIM:617391) variants versus controls in methylation array data from peripheral blood-derived DNA and reported 19 DMRs called with DMRcate (Fischer P<0.01, 887 betacutoff=0.05, minCpG=5)⁸⁴. The comparative number of DMRs we derived for CHD2 versus 888 control methylation array data under the same conditions using DMRcate is 474 DMRs. This 889 890 increased number of DMRs may represent the inherent function of CHD2 as a chromatin remodeler that interacts directly with the DNA, whereas HNRNPU forms complexes with RNA. 891 Furthermore, a subset of CHD2 episignature probes overlap with DMRs in the TSS/5'UTR of 892 893 developmentally relevant genes and might regulate expression (Table S7). For instance, a cluster 894 of hypermethylated episignature probes for the CHD2 450K and 850K episignatures are contained within a larger hypermethylated DMR in the TSS and 5'UTR of HOXA4 (Figure S31). 895 However, HOXA4 is not expressed in the blood, and, therefore, would not be expected to be 896 897 impacted by differential methylation. Thus, we have shown that CHD2 is associated with DMRs 898 in the blood that correspond with the episignature. Our work suggests that future studies should 899 investigate the CHD2 episignature in disease-relevant tissue types where DMRs are likely to 900 contribute directly to gene dysregulation and disease pathogenesis.

Here, we have utilized various DNA methylation analyses to identify causative and candidate etiologies in 2% of our cohort of 516 individuals with unsolved DEEs. While DNA methylation does not explain the majority of DEEs, methylation array yield is comparable to the current added utility of GS^{4,73} and remains a low-cost approach that can detect missed genetic etiologies and propose new molecular candidates. Importantly, this yield is expected to increase over time as we interrogate the functional consequences of rare DMRs and better understand

907 which genes and pathways exhibit episignatures, including unraveling inconclusive episignature 908 results. We have also investigated the episignature for the DEE gene CHD2 in-depth and have 909 provided evidence that the CHD2 episignature is associated with DMRs. DMRs may affect gene 910 expression, especially in disease-relevant tissue types. Furthermore, CHD2 episignatures and 911 associated DMRs may have potential as a biomarker readout for therapeutic testing, as the DNA methylation might potentially be reversed with targeted treatment. Thus, our work highlights the 912 913 impact of investigating DNA methylation in DEEs, both for the genetic diagnosis of unsolved cases 914 and to augment our understanding of underlying disease function toward the future development of targeted therapies. 915

917 Declaration of Interests

B.S. is a shareholder in EpiSign Inc, a company involved in commercialization of EpiSign[™] 918 software. D.E.M is on a scientific advisory board at ONT and has received travel support from 919 ONT to speak on their behalf. D.E.M is engaged in a research agreement with ONT. D.E.M holds 920 921 stock options in MyOme. I.E.S. has served on scientific advisory boards for BioMarin, Chiesi, 922 Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Nutricia, Rogcon, Takeda Pharmaceuticals, UCB, Xenon Pharmaceuticals, Cerecin; has received speaker honoraria from 923 924 GlaxoSmithKline, UCB, BioMarin, Biocodex, Chiesi, Liva Nova, Nutricia, Zuellig Pharma, Stoke 925 Therapeutics and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin, Encoded Therapeutics Stoke Therapeutics and Eisai; has served as an investigator for 926 Anavex Life Sciences, Cerevel Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, 927 928 Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, 929 Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix and Zynerba; has consulted for Care Beyond Diagnosis, Epilepsy Consortium, Atheneum Partners, Ovid 930 Therapeutics, UCB, Zynerba Pharmaceuticals, BioMarin, Encoded Therapeutics and Biohaven 931 932 Pharmaceuticals; and is a Non-Executive Director of Bellberry Ltd and a Director of the Australian 933 Academy of Health and Medical Sciences and the Australian Council of Learned Academies 934 Limited. I.E.S. may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has a patent for SCN1A testing held by Bionomics Inc and licensed to 935 various diagnostic companies; has a patent molecular diagnostic/theragnostic target for benign 936 937 familial infantile epilepsy (BFIE) [PRRT2] 2011904493 & 2012900190 and PCT/AU2012/001321 (TECH ID:2012-009). L.G.S. receives funding from the Health Research Council of New Zealand 938 and Cure Kids New Zealand, is a consultant for the Epilepsy Consortium, and has received travel 939 grants from Segirus and Nutricia. L.G.S. has received research grants and consultancy fees from 940 941 Zynerba Pharmaceuticals and has served on and Takeda and Eisai Pharmaceuticals scientific

advisory panels. The Department of Molecular and Human Genetics at Baylor College of Medicine
 receives revenue from clinical genetic testing conducted at Baylor Genetics Laboratories.

944

945 Acknowledgments

We thank all the individuals and their families for participating in this research. Major funding for 946 this project was provided by a grant (#631106) from Citizens United for Research in Epilepsy 947 948 (CURE). A subset of DNA methylation arrays was provided by the University of Washington Center for Rare Disease Research (UW-CRDR), formerly known as the Center for Mendelian 949 Genomics (CMG), with support from NHGRI grants U01 HG011744, UM1 HG006493 and U24 950 HG011746 and with enthusiastic support from the late Debbie Nickerson. We gratefully 951 952 acknowledge support from the Australian Epilepsy Research Foundation grant, Australian National Health and Medical Research Council (NHMRC) Centre for Research Excellence Grant 953 (GNT2006841), NHMRC Synergy Grant (GNT2010562), the Health Research Council of New 954 955 Zealand, Cure Kids New Zealand, and the Estate of Ernest Hyam Davis and the Tedd and Mollie 956 Carr Endowment Trust. We acknowledge the Epi25 Consortium, which provided exome sequence data for review for a subset of individuals. C.W.L. has been funded through the American Epilepsy 957 958 Society (AES) predoctoral fellowship and the St. Jude Graduate School of Biomedical Sciences. We would also like to acknowledge the inaugural St. Jude Biohackathon 2022 for coordinating 959 960 the event that led to a team comprised of C.W.L., P.K., M.D., and W.R., who assembled the MethylMiner pipeline described here. D.E.M. is supported by NIH grant DP5OD033357. Research 961 reported in this manuscript by M.W.H., S.K., H.D., K.C.W., J.A.R., and H.T.C., was supported by 962 963 the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director 964 under Award Numbers U01HG007709 and U01HG007942. K.L.P. has been funded through the GRIN2B foundation and CURE. I.E.S. is also supported by a NHMRC Senior Investigator 965

966	Fellowship (GNT1172897). We acknowledge Pratibha Kottapalli and Sanchit Trivedi from the St.
967	Jude Hartwell Center who performed Illumina sequencing for this project. The content is solely
968	the responsibility of the authors and does not necessarily represent the official views of the NIH.
969	
970	Data and Code Availability
971	Methylation array data for individuals with unsolved DEEs and those with pathogenic variants in
972	CHD2 who have given consent for data sharing will be made available through dbGaP. Additional
973	data requests can be directed to H.C.M. The methylation array analysis pipeline used in part of
974	this study for epivariant detection can be accessed on GitHub: https://github.com/stjude-
975	biohackathon/MethylMiner. EpiSign [™] is proprietary commercial software and is not publicly
976	available.
977	

978 Supplemental Information

979 Supplemental phenotype data, methods, and figures are in the supplemental documents section.

Scheffer, I. E. et al. ILAE classification of the epilepsies: Position paper of the ILAE

981 **<u>REFERENCES</u>**

1

982

983 Commission for Classification and Terminology. *Epilepsia* 58, 512-521 (2017). https://doi.org/10.1111/epi.13709 984 Oliver, K. L. et al. Genes4Epilepsy: An epilepsy gene resource. Epilepsia 64, 1368-1375 985 2 (2023). https://doi.org/10.1111/epi.17547 986 987 3 Poke, G., Stanley, J., Scheffer, I. E. & Sadleir, L. G. Epidemiology of Developmental and 988 Epileptic Encephalopathy and of Intellectual Disability and Epilepsy in Children. Neurology 100, e1363-e1375 (2023). https://doi.org/10.1212/WNL.000000000206758 989 4 Palmer, E. E. et al. Integrating exome sequencing into a diagnostic pathway for epileptic 990 991 encephalopathy: Evidence of clinical utility and cost effectiveness. Mol Genet Genomic 992 Med 6, 186-199 (2018). https://doi.org/10.1002/mgg3.355 McTague, A., Howell, K. B., Cross, J. H., Kurian, M. A. & Scheffer, I. E. The genetic 993 5 994 landscape of the epileptic encephalopathies of infancy and childhood. The Lancet Neurology 15, 304-316 (2016). https://doi.org/10.1016/s1474-4422(15)00250-1 995 996 6 Sanchez Fernandez, I., Loddenkemper, T., Gainza-Lein, M., Sheidley, B. R. & Poduri, A. 997 Diagnostic yield of genetic tests in epilepsy: A meta-analysis and cost-effectiveness study. Neurology (2019). https://doi.org/10.1212/WNL.00000000006850 998 999 7 Symonds, J. D. & McTague, A. Epilepsy and developmental disorders: Next generation sequencing in the clinic. Eur J Paediatr Neurol 24, 15-23 (2020). 1000 https://doi.org/10.1016/j.ejpn.2019.12.008 1001 Mefford, H. C. et al. Rare copy number variants are an important cause of epileptic 8 1002 encephalopathies. Ann Neurol 70, 974-985 (2011). https://doi.org/10.1002/ana.22645 1003 1004 9 A roadmap for precision medicine in the epilepsies. The Lancet Neurology 14, 1219-1228 (2015). https://doi.org/10.1016/s1474-4422(15)00199-4 1005 10 Bayat, A., Bayat, M., Rubboli, G. & Moller, R. S. Epilepsy Syndromes in the First Year of 1006 Life and Usefulness of Genetic Testing for Precision Therapy. Genes (Basel) 12 (2021). 1007 https://doi.org/10.3390/genes12071051 1008 11 D'Gama, A. M. et al. Evaluation of the feasibility, diagnostic yield, and clinical utility of 1009 rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, 1010 multicentre, pilot cohort study. Lancet Neurol 22, 812-825 (2023). 1011 1012 https://doi.org/10.1016/S1474-4422(23)00246-6 Sheidley, B. R. et al. Genetic testing for the epilepsies: A systematic review. Epilepsia 12 1013 (2021). https://doi.org/10.1111/epi.17141 1014 13 Moore, L. D., Le, T. & Fan, G. DNA methylation and its basic function. 1015 Neuropsychopharmacology 38, 23-38 (2013). https://doi.org/10.1038/npp.2012.112 1016 1017 14 Garg, P. et al. A Survey of Rare Epigenetic Variation in 23,116 Human Genomes Identifies Disease-Relevant Epivariations and CGG Expansions. Am J Hum Genet 107, 1018 654-669 (2020). https://doi.org/10.1016/j.ajhg.2020.08.019 1019 1020 15 LaCroix, A. J. et al. GGC Repeat Expansion and Exon 1 Methylation of XYLT1 Is a Common Pathogenic Variant in Baratela-Scott Syndrome. Am J Hum Genet 104, 35-44 1021 (2019), https://doi.org/10.1016/i.aihg.2018.11.005 1022 Barbosa, M. et al. Identification of rare de novo epigenetic variations in congenital 1023 16 disorders. Nat Commun 9, 2064 (2018). https://doi.org/10.1038/s41467-018-04540-x 1024 Levy, M. A. et al. Novel diagnostic DNA methylation episignatures expand and refine the 1025 17 1026 epigenetic landscapes of Mendelian disorders. Human Genetics and Genomics 1027 Advances (2021). https://doi.org/10.1016/j.xhgg.2021.100075

1028 1029	18	Aref-Eshghi, E. <i>et al.</i> Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders. <i>Am J Hum</i>
1030		Genet 106 , 356-370 (2020). <u>https://doi.org/10.1016/j.ajhg.2020.01.019</u>
1031	19	Sadikovic, B. et al. Clinical epigenomics: genome-wide DNA methylation analysis for the
1032		diagnosis of Mendelian disorders. <i>Genet Med</i> 23 , 1065-1074 (2021).
1033		https://doi.org/10.1038/s41436-020-01096-4
1034	20	Levy, M. A. et al. Functional correlation of genome-wide DNA methylation profiles in
1035		genetic neurodevelopmental disorders. <i>Hum Mutat</i> 43 , 1609-1628 (2022).
1036		https://doi.org/10.1002/humu.24446
1037	21	Carvill, G. L. et al. Targeted resequencing in epileptic encephalopathies identifies de
1038		novo mutations in CHD2 and SYNGAP1. <i>Nat Genet</i> 45 , 825-830 (2013).
1039		https://doi.org/10.1038/ng.2646
1040	22	Scheffer, I. E. et al. Exome sequencing for patients with developmental and epileptic
1041		encephalopathies in clinical practice. Dev Med Child Neurol 65, 50-57 (2023).
1042		https://doi.org/10.1111/dmcn.15308
1043	23	Parkinson Progression Marker, I. The Parkinson Progression Marker Initiative (PPMI).
1044		Prog Neurobiol 95 , 629-635 (2011). <u>https://doi.org/10.1016/j.pneurobio.2011.09.005</u>
1045	24	Pidsley, R. et al. Critical evaluation of the Illumina MethylationEPIC BeadChip
1046		microarray for whole-genome DNA methylation profiling. Genome Biol 17 , 208 (2016).
1047		<u>https://doi.org/10.1186/s13059-016-1066-1</u>
1048	25	Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the
1049		analysis of Infinium DNA methylation microarrays. <i>Bioinformatics</i> 30 , 1363-1369 (2014).
1050		https://doi.org/10.1093/bioinformatics/btu049
1051	26	Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package
1052		for removing batch effects and other unwanted variation in high-throughput experiments.
1053		Bioinformatics 28, 882-883 (2012). https://doi.org/10.1093/bioinformatics/bts034
1054	27	Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression
1055		data using empirical Bayes methods. <i>Biostatistics</i> 8 , 118-127 (2007).
1056		https://doi.org/10.1093/biostatistics/kxj037
1057	28	Jaffe, A. E. & Irizarry, R. A. Accounting for cellular heterogeneity is critical in epigenome-
1058		wide association studies. Genome Biology 15, R31 (2014). https://doi.org/10.1186/gb-
1059		<u>2014-15-2-r31</u>
1060	29	Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime
1061		cis-regulatory elements required for macrophage and B cell identities. Mol Cell 38, 576-
1062		589 (2010). https://doi.org/10.1016/j.molcel.2010.05.004
1063	30	Court, F. et al. Genome-wide parent-of-origin DNA methylation analysis reveals the
1064		intricacies of human imprinting and suggests a germline methylation-independent
1065		mechanism of establishment. <i>Genome Res</i> 24 , 554-569 (2014).
1066		https://doi.org/10.1101/gr.164913.113
1067	31	Zhou, W., Laird, P. W. & Shen, H. Comprehensive characterization, annotation and
1068		innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res 45,
1069		e22 (2017). https://doi.org/10.1093/nar/gkw967
1070	32	Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A. & McKusick, V. A. Online
1071		Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic
1072		disorders. Nucleic Acids Res 33, D514-517 (2005). https://doi.org/10.1093/nar/gki033
1073	33	Robinson, J. T. et al. Integrative genomics viewer. Nature Biotechnology 29, 24-26
1074		(2011). <u>https://doi.org/10.1038/nbt.1754</u>
1075	34	Vaisvila, R. et al. Enzymatic methyl sequencing detects DNA methylation at single-base
1076		resolution from picograms of DNA. Genome Res 31 , 1280-1289 (2021).
1077		https://doi.org/10.1101/gr.266551.120

1078 1079	35	Miller, D. E. <i>et al.</i> Targeted long-read sequencing identifies missing disease-causing variation. <i>Am J Hum Genet</i> 108 , 1436-1449 (2021).
1080		https://doi.org/10.1016/j.ajhg.2021.06.006
1081	36	Li, H. Minimap2: pairwise alignment for nucleotide sequences. <i>Bioinformatics</i> 34 , 3094-
1082		3100 (2018). https://doi.org/10.1093/bioinformatics/bty191
1083	37	Zheng, Z. et al. Symphonizing pileup and full-alignment for deep learning-based long-
1084		read variant calling. Nature Computational Science 2, 797-803 (2022).
1085		https://doi.org/10.1038/s43588-022-00387-x
1086	38	Sedlazeck, F. J. et al. Accurate detection of complex structural variations using single-
1087		molecule sequencing. Nat Methods 15, 461-468 (2018). https://doi.org/10.1038/s41592-
1088		<u>018-0001-7</u>
1089	39	Heller, D. & Vingron, M. SVIM: structural variant identification using mapped long reads.
1090		Bioinformatics 35, 2907-2915 (2019). https://doi.org/10.1093/bioinformatics/btz041
1091	40	Jiang, T. et al. Long-read-based human genomic structural variation detection with
1092		cuteSV. Genome Biol 21, 189 (2020). https://doi.org/10.1186/s13059-020-02107-y
1093	41	Lin, J. H., Chen, L. C., Yu, S. C. & Huang, Y. T. LongPhase: an ultra-fast chromosome-
1094		scale phasing algorithm for small and large variants. <i>Bioinformatics</i> 38 , 1816-1822
1095		(2022). https://doi.org/10.1093/bioinformatics/btac058
1096	42	EpiSign v4 Menu, https://episign.lhsc.on.ca/img/EpiSign_v4_Menu.pdf).
1097	43	Platt, J. C. Probabilistic outputs for support vector machines and comparisons to
1098		regularized likelihood methods. Advances in Large Margin Classifiers 10 (2000).
1099	44	Sadikovic, B., Levy, M. A. & Aref-Eshghi, E. Functional annotation of genomic variation:
1100		DNA methylation episignatures in neurodevelopmental Mendelian disorders. Hum Mol
1101		Genet 29, R27-R32 (2020). https://doi.org/10.1093/hmg/ddaa144
1102	45	FastQC: A Quality Control Tool for High Throughput Sequence Data (2010).
1103	46	Dobin, A. et al. STAR: ultrafast universal RNA-seg aligner. Bioinformatics 29, 15-21
1104		(2013). https://doi.org/10.1093/bioinformatics/bts635
1105	47	Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast
1106		and bias-aware quantification of transcript expression. Nat Methods 14, 417-419 (2017).
1107		https://doi.org/10.1038/nmeth.4197
1108	48	Brechtmann, F. et al. OUTRIDER: A Statistical Method for Detecting Aberrantly
1109		Expressed Genes in RNA Sequencing Data. Am J Hum Genet 103 , 907-917 (2018).
1110		https://doi.org/10.1016/j.ajhg.2018.10.025
1111	49	Yépez, V. A., Murdock, D. R. & Lee, B. Gene expression counts from fibroblast, strand-
1112		specific, BCM UDN. Zenodo (2020). https://doi.org/10.5281/zenodo.3963474
1113	50	Aref-Eshghi, E. et al. BAFopathies' DNA methylation epi-signatures demonstrate
1114		diagnostic utility and functional continuum of Coffin-Siris and Nicolaides-Baraitser
1115		syndromes. Nat Commun 9, 4885 (2018). https://doi.org/10.1038/s41467-018-07193-y
1116	51	Aref-Eshghi, E. et al. Genomic DNA Methylation Signatures Enable Concurrent
1117		Diagnosis and Clinical Genetic Variant Classification in Neurodevelopmental
1118		Syndromes. Am J Hum Genet 102 , 156-174 (2018).
1119		https://doi.org/10.1016/j.ajhg.2017.12.008
1120	52	Aref-Eshghi, E. et al. Diagnostic Utility of Genome-wide DNA Methylation Testing in
1121		Genetically Unsolved Individuals with Suspected Hereditary Conditions. Am J Hum
1122		Genet 104, 685-700 (2019). https://doi.org/10.1016/j.ajhg.2019.03.008
1123	53	Ho, D. E., Imai, K., King, G. & Stuart, E. A. Matching as Nonparametric Preprocessing
1124		for Reducing Model Dependence in Parametric Causal Inference. Political Analysis 15,
1125		199-236 (2017). https://doi.org/10.1093/pan/mpl013
1126	54	Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing
1127		and microarray studies. Nucleic Acids Res 43, e47 (2015).
1128		https://doi.org/10.1093/nar/gkv007

1129 1130	55	Houseman, E. A. <i>et al.</i> DNA methylation arrays as surrogate measures of cell mixture distribution <i>BMC Bioinformatics</i> 13 86 (2012) https://doi.org/10.1186/1471-2105-13-86
1131	56	Gu Z Gu L Fils R Schlesner M & Brors B circlize Implements and enhances
1122	00	circular visualization in R. <i>Bioinformatics</i> 30 , 2811-2812 (2014)
1122		https://doi.org/10.1003/bioinformatics/btu/303
112/	57	Cavalcante R. G. & Sartor, M. A. annotatr: genomic regions in context. <i>Bioinformatics</i>
1125	51	33 2381 2383 (2017) https://doi.org/10.1003/bioinformatics/btv183
1126	58	TrooAndLoaf: Displaying binary troos with focus on dendrogram loaves (P nackage
1127	50	version 1 12.0 2023)
1120	50	Fortin I. D. at al. Eurotional normalization of 450k mathylation array data improves
1120	59	ronlightion in Jargo concer studios. <i>Concerno Riology</i> 15 , 503 (2014)
1139		$\frac{1}{1000} \frac{1}{1000} \frac{1}{1000$
1140	60	Intps.//doi.org/10.1160/S13039-014-0303-2
1141	00	salie, A. E. <i>et al.</i> bump numing to identify differentially memorated regions in epigenetic
1142		epidemiology studies. <i>Int J Epidemiol</i> 41 , 200-209 (2012).
1143	61	<u>nups://doi.org/10.1093/ije/dyr238</u>
1144	01	Peters, T. J. <i>et al.</i> De novo identification of differentially methylated regions in the numan
1145	<u></u>	genome. Epigenetics & Chromatin 8 , 6 (2015). <u>https://doi.org/10.1186/1756-8935-8-6</u>
1146	62	Peters, I. J. et al. Calling differentially methylated regions from whole genome disulphite
1147		sequencing with DMRCate. Nucleic Acids Res 49, e109 (2021).
1148	<u></u>	<u>nttps://doi.org/10.1093/nar/gkab637</u>
1149	63	Wu, H. <i>et al.</i> Detection of differentially methylated regions from whole-genome disulfite
1150		sequencing data without replicates. <i>Nucleic Acids Res</i> 43 , e141 (2015).
1151	0.4	nttps://doi.org/10.1093/nar/gkv715
1152	64	I sutsumi, M. et al. A female patient with retinoblastoma and severe intellectual disability
1153		carrying an X;13 balanced translocation without rearrangement in the RB1 gene: a case
1154	05	report. BMC Med Genomics 12, 182 (2019). <u>https://doi.org/10.1186/s12920-019-0640-2</u>
1155	65	Chen, X. et al. A de novo pathogenic CSINKTE mutation identified by exome sequencing
1156		in family trios with epileptic encephalopathy. <i>Hum Mutat</i> 40 , 281-287 (2019).
115/	00	<u>https://doi.org/10.1002/humu.23690</u>
1158	66	Sobreira, N., Schlettecatte, F., Valle, D. & Hamosh, A. Geneivatcher: a matching tool for
1159		connecting investigators with an interest in the same gene. Hum Mutat 36, 928-930
1160	~-	(2015). <u>https://doi.org/10.1002/humu.22844</u>
1161	67	Winnepenninckx, B. et al. CGG-repeat expansion in the DIP2B gene is associated with
1162		the fragile site FRA12A on chromosome 12q13.1. Am J Hum Genet 80, 221-231 (2007).
1163		https://doi.org/10.1086/510800
1164	68	Kiedrowski, L. A. et al. DNA methylation assay for X-chromosome inactivation in female
1165		human iPS cells. Stem Cell Rev Rep 7, 969-975 (2011). https://doi.org/10.1007/s12015-
1166	~~	<u>011-9238-6</u>
1167	69	conumee: Enhanced copy-number variation analysis using Illumina DNA methylation
1168		arrays.
1169	70	Harada, A. <i>et al.</i> Chd2 interacts with H3.3 to determine myogenic cell fate. <i>EMBO J</i> 31 ,
1170		2994-3007 (2012). <u>https://doi.org/10.1038/emboj.2012.136</u>
1171	71	Lamar, K. J. & Carvill, G. L. Chromatin Remodeling Proteins in Epilepsy: Lessons From
1172		CHD2-Associated Epilepsy. Front Mol Neurosci 11, 208 (2018).
1173		https://doi.org/10.3389/fnmol.2018.00208
1174	72	Geeleher, P. et al. Gene-set analysis is severely biased when applied to genome-wide
1175		methylation data. <i>Bioinformatics</i> 29 , 1851-1857 (2013).
1176		https://doi.org/10.1093/bioinformatics/btt311
1177	73	Altares, A. et al. Whole-genome sequencing offers additional but limited clinical utility
1178		compared with reanalysis of whole-exome sequencing. Genet Med 20, 1328-1333
1179		(2018). <u>https://doi.org/10.1038/gim.2018.41</u>

1180	74	Palmer, E. E. et al. Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic
1181		Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies.
1182		Neurology 96, e1770-e1782 (2021). https://doi.org/10.1212/WNL.000000000011655
1183	75	Vielhaber, E., Eide, E., Rivers, A., Gao, Z. H. & Virshup, D. M. Nuclear entry of the
1184		circadian regulator mPER1 is controlled by mammalian casein kinase I epsilon. Mol Cell
1185		Biol 20, 4888-4899 (2000). https://doi.org/10.1128/mcb.20.13.4888-4899.2000
1186	76	Lee, C., Weaver, D. R. & Reppert, S. M. Direct association between mouse PERIOD
1187		and CKIepsilon is critical for a functioning circadian clock. Mol Cell Biol 24, 584-594
1188		(2004). https://doi.org/10.1128/mcb.24.2.584-594.2004
1189	77	Toh, K. L. et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase
1190		syndrome. Science 291, 1040-1043 (2001). https://doi.org/10.1126/science.1057499
1191	78	Zhou, L. et al. The circadian clock gene Csnk1e regulates rapid eye movement sleep
1192		amount, and nonrapid eye movement sleep architecture in mice. Sleep 37 , 785-793,
1193		793A-793C (2014). <u>https://doi.org/10.5665/sleep.3590</u>
1194	79	Leitao, E. et al. Systematic analysis and prediction of genes associated with monogenic
1195		disorders on human chromosome X. Nat Commun 13, 6570 (2022).
1196		https://doi.org/10.1038/s41467-022-34264-y
1197	80	Platzer, K. et al. De Novo Missense Variants in SLC32A1 Cause a Developmental and
1198		Epileptic Encephalopathy Due to Impaired GABAergic Neurotransmission. Ann Neurol
1199		92, 958-973 (2022). <u>https://doi.org/10.1002/ana.26485</u>
1200	81	Cappuccio, G. et al. De novo SMARCA2 variants clustered outside the helicase domain
1201		cause a new recognizable syndrome with intellectual disability and blepharophimosis
1202		distinct from Nicolaides-Baraitser syndrome. Genet Med 22, 1838-1850 (2020).
1203		https://doi.org/10.1038/s41436-020-0898-y
1204	82	Liu, P. et al. Reanalysis of Clinical Exome Sequencing Data. N Engl J Med 380, 2478-
1205		2480 (2019). https://doi.org/10.1056/NEJMc1812033
1206	83	Nurk, S. et al. The complete sequence of a human genome. Science 376, 44-53 (2022).
1207		https://doi.org/10.1126/science.abj6987
1208	84	Rooney, K. et al. DNA methylation episignature and comparative epigenomic profiling of
1209		HNRNPU-related neurodevelopmental disorder. Genet Med, 100871 (2023).
1210		https://doi.org/10.1016/j.gim.2023.100871
1211		

1213

Tables and Table Legends

Table 1. Summary of epivariants and underlying DNA defects identified in this study.						
Location	Gene	Direction	Underlying DNA Defect	Inheritance	Probands (n)	
chr13	chr13:multiple	Hyper	X;13 translocation (p)	De novo	1	
Xp22	BCLAF3	Hyper	CGG repeat (c)	De novo	1	
22q13	CSNK1E	Hyper	CGG repeat (c)	Inherited	2 + 1 match	
12q13	DIP2B	Hyper	CGG repeat (c)	Inherited	1	
2p16	CFAP36/CCDC104	Hyper	Tandem duplication (b)	Inherited	1	
2q37.3	chr2:multiple	Нуро	Deletion (b)	Inherited	1	
15q24	LINGO1	Нуро	Deletion (b)	Inherited	4	

List of epivariation findings from screening cohort with unsolved DEEs for rare outlier DNA methylation changes. Molecular findings are considered p=pathogenic, c=candidate, and b=benign.

1214

Table 2. Summary of episignatures and causative sequence variants identified in this study.							
Gene	Signature	MVP	Genomic Variant (I	hg38)	Consequence	Inheritance	
ANKRD11	KGBS/	0.854	chr16:89284030	G>A	p.Arg838Ter (p)	De novo	
	MRD23						
		0.989	chr16:89279671	C>A	p.Glu2291Ter (p)	De novo	
SETD1B	IDDSELD	0.763	chr12:121822939	C>T	p.Arg1454Ter (p)	Unknown	
TET3	BEFAHRS	0.327	chr2:74102031	dup	p.Thr1749HisfsTer5 (p)	Inherited	
UBE2A	MRXSN	0.149	chrX:119583172	G>A	p.Ala126Thr (p)	Inherited	
KDM2B	KDM2B	0.982	chr12:121520986	C>G	p.Arg349Pro (u)	Inherited	
List of episignature findings from screening unsolved. Methylation Variant Pathogenicity (MVP) scores shown. Molecular							
findings are considered p=pathogenic or u=variant of uncertain significance.							

1216

Figures and Figure Legends



1217

1218 Figure 1: Rare outlier DMR analysis identifies chromosomal hypermethylation caused by X;13 translocation. A. Graphical representation of chr13 rare hypermethylation events in a proband 1219 1220 with unsolved DEE. The upper portion of the track displays the genes on chr13 for which hypermethylation events were called. The two grey panels (upper=line, lower=dot) depict β-1221 values for the average of the proband's array replicates (red) and the average of the parents' 1222 1223 array data (black) for a representative probe within each DMR (n=27). Subtle hypermethylation 1224 hovering around ~25% can be seen for the proband compared to the parents. The lower track shows chromosomal locations of the DMRs of the X;13 translocation. **B.** Pedigree showing that 1225

- 1226 chr13 hypermethylation events and the X;13 translocation occured *de novo*. **C**. IGV view of ONT
- 1227 LRS data for chrX (left) and chr13 (right). Some, but not all, reads spanning the translocation are
- 1228 colored to show that they span the breakpoint.



Figure 2: Rare outlier DMR analysis identifies tandem repeat expansions. A. DMR plot depicting
outlier hypermethylation of the *CSNK1E* 5'UTR and intron 1 in two probands with unsolved DEEs
(three replicates across both for a total of five samples), one parent, and one unaffected control

1234 (total n=7 red lines) detected through epivariation analysis. **B.** The upper panel shows expression 1235 values from RNA-seq of human-derived fibroblasts for individuals with CSNK1E hypermethylation 1236 compared to control methylation levels. Significance between groups was determined by a two-1237 tailed paired t-test (p=0.029 for gene counts and p=0.0169 for transcripts per million or TPM). A 1238 representative predicted expression plot from drop-out analysis using the OUTRIDER algorithm is shown at the lower portion of the panel. See Figure S9 for the individual OUTRIDER plots for 1239 1240 each family and significance information. **C.** Unphased IGV view of LRS data showing CpG sites that are methylated (red) and unmethylated (blue). The CGG repeat expansion seen in the 1241 proband was inherited from the parent and is shown as purple squares denoting insertions in the 1242 1243 reads (black arrows); not all reads that are methylated show the insertion as they terminated 1244 within the inserted sequence and are clipped by the alignment process.

1246



Figure 3: Summary Methylation Variant Pathogenicity (MVP) score for all individuals positive for EpisignTM v4 Episignature classifier. Final classification for a specific EpiSignTM disorder includes a combination of MVP score, hierarchical clustering, and analysis. A Methylation Variant Pathogenicity (MVP) score (between 0 and 1) was generated to represent the confidence of prediction for the specific episignature on the EpiSignTM v4 clinical classifier that the SVM was trained to detect. Each colored circle represents a different individual and its associated MVP score for each of the episignatures on the EpiSignTM v4 clinical multidimensional scaling (MDS) review.





Figure 4: Insights from the *CHD2* Episignature. **A**. Multidimensional scaling (MDS) plot showing clustering of individuals with pathogenic *CHD2* variants (red, upper) for the previously described *CHD2* 450K (n=9) episignature with shared 450K and 850K array probes clusters away from the controls (blue) The refined *CHD2* 850K (n=29) episignature (red, lower) clusters away from unaffected controls (blue). **B**. Circos plot representing shared probes between episignatures. Differentially methylated probes (DMPs) shared between the CHD2 850K cohort (bold red), CHD2

1254 450K cohort (red), and 55 other episionatures on EpiSign with functional correlation analysis 1255 previously published²⁰. The thickness of the connecting lines corresponds to the number of probes 1256 shared between the cohorts. C. Tree and leaf visualization of Euclidean clustering of 1257 episignatures. Tree and leaf visualization for all 57 cohorts using the top 500 DMPs for each group 1258 (for cohorts with less than 500 DMPs, all DMPS were used). Cohort samples were aggregated using the median value of each probe within a group. A leaf node represents a cohort, with node 1259 1260 sizes illustrating relative scales of the number of selected DMPs for the respective cohort, and node colors are indicative of the global mean methylation difference, a gradient of 1261 hypomethylation (blue) or hypermethylation (red). D. Circular karyotype plot showing overlap of 1262 CHD2 450K episignature probes (inner circle, n=200), with CHD2 850K episignature probes 1263 (middle circle, n=200), and WGBS DMRs derived with at least a 15% methylation difference for 1264 1265 the condensed visual representation (outer circle, n=411). Each line depicts a probe or DMR 1266 where red denotes hypermethylation and blue denotes hypomethylation. The purple tracks depict 1267 coverage of the 450K array probes (inner), 850K EPIC array probes (middle), and WGBS reads 1268 (outer). Refer to Figure S29 for linear karyotype DMR plots for chr1-22.